This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
B. Braun Melsungen AG
Drug Names(s): benzoate and phenylacetate
Ucephan is a 10% sodium benzoate and 10% sodium phenylacetate oral solution. Ucephan works by scavenging ammonia through a reaction with glycine (in the case of benzoate) or glutamine (in the case of phenylacetate) to form water-soluble and renally excretable compounds (benzoylglycine or hippurate and phenylacetylglutamine, respectively) that eliminate ammonia through the urine. It bypasses the urea cycle and requires intact renal function for elimination of ammonia.
IVAX and Mcgaw
IVAX and McGaw announced that they have entered into a definitive merger agreement.
Under the agreement, approved by the boards of directors of both companies, McGaw will become a wholly owned subsidiary of IVAX. In the merger, McGaw stockholders will receive $16 per share in IVAX common stock based on the average closing prices of IVAX common stock for the 10 consecutive trading day period ending two trading days prior to the effective date of the merger. McGaw currently has approximately 27.4 million shares outstanding, including warrants and options, resulting in a transaction value of approximately $440 million. IVAX has approximately 72.2 million shares outstanding.
IVAX and B. Braun
IVAX and B. Braun Melsungen AG announced that IVAX and B. Braun of America, a wholly-owned subsidiary of B. Braun Melsungen AG, have entered into a definitive agreement relating to the sale of McGaw, a wholly-owned subsidiary of IVAX that develops,...See full deal structure in Biomedtracker
Pink Sheet AHP's Alredase (tolrestat)
Pink Sheet Patent extension requests
Additional information available to subscribers only: